{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:59Z","timestamp":1793731079539,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute medication effectiveness using the 4-item Migraine Treatment Optimization Questionnaire (mTOQ-4) to measure acute medication optimization over 4\u00a0weeks post-infusion.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n RELIEF was a 12-week, phase 3, multicenter, parallel-group, double-blind, placebo-controlled clinical trial conducted in patients aged 18\u201375\u00a0years with a\u2009\u2265\u20091-year history of migraine and 4\u201315 migraine days per month in the 3\u00a0months prior to screening. Patients were randomized 1:1 to a 30-min infusion of eptinezumab 100\u00a0mg or placebo within 1\u20136\u00a0h of a qualifying migraine attack. The mTOQ-6 and 6-item Headache Impact Test (HIT-6) were administered at screening visit and week 4. From the mTOQ-6, we calculated the mTOQ-4 using the following items: \u201c2-h pain free,\u201d \u201c24-h relief,\u201d \u201cable to plan,\u201d and \u201cfeeling in control\u201d to measure acute medication optimization.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n A total of 238 patients received eptinezumab 100\u00a0mg and 226 provided week 4 data; 242 received placebo and 232 provided week 4 data. In the eptinezumab arm, the proportion of\u00a0patients with moderate\/maximal optimization increased from 31.4% at baseline to 58.0% (26.6 percentage point increase) at week 4. The corresponding proportions in the placebo group were 40.5% to 50.4% (9.9 percentage point increase). Eptinezumab treatment was associated with numerically larger improvements in HIT-6 at week 4. Relative improvements with eptinezumab vs. placebo from baseline to week 4 in HIT-6 were greater in those with poor treatment optimization at baseline.<\/jats:p>\n <\/jats:sec>\n Conclusions<\/jats:title>\n In comparison with placebo, treatment with eptinezumab was associated with improvements in acute medication optimization as measured by mTOQ and reductions in headache impact, as measured by HIT-6. These benefits were greater in those with poor acute treatment optimization prior to preventive treatment with eptinezumab.<\/jats:p>\n <\/jats:sec>\n Trial registration<\/jats:title>\n ClinicalTrials.gov identifier: NCT04152083<\/jats:ext-link>.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s10194-022-01463-3","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T20:03:42Z","timestamp":1659038622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study"],"prefix":"10.1186","volume":"23","author":[{"given":"Roger","family":"Cady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Krog","family":"Josiassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Lindsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"1463_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s1474-4422(18)30322-3","volume":"17","author":"GBD","year":"2016","unstructured":"GBD (2016) Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954\u2013976. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"key":"1463_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/S10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23:34. https:\/\/doi.org\/10.1186\/S10194-022-01402-2","journal-title":"J Headache Pain"},{"key":"1463_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurol 68:343\u2013349. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurol"},{"issue":"4","key":"1463_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/head.14103","volume":"61","author":"DC Buse","year":"2021","unstructured":"Buse DC, Armand CE, Charleston L et al (2021) Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. Headache 61(4):628\u2013641. https:\/\/doi.org\/10.1111\/head.14103","journal-title":"Headache"},{"key":"1463_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013221. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"1463_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1212\/01.CON.0000418641.45522.3b","volume":"18","author":"PB Rizzoli","year":"2012","unstructured":"Rizzoli PB (2012) Acute and Preventive Treatment of Migraine. Continuum Lifelong Learning Neurology 18:764\u2013782","journal-title":"Continuum Lifelong Learning Neurology"},{"key":"1463_CR7","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/head.13835","volume":"60","author":"L Lombard","year":"2020","unstructured":"Lombard L, Ye W, Nichols R et al (2020) A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment. Headache 60:1325\u20131339. https:\/\/doi.org\/10.1111\/head.13835","journal-title":"Headache"},{"key":"1463_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/S40263-021-00818-9","volume":"35","author":"C Sun-Edelstein","year":"2021","unstructured":"Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A (2021) The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update. CNS Drugs 35:545\u2013565. https:\/\/doi.org\/10.1007\/S40263-021-00818-9","journal-title":"CNS Drugs"},{"key":"1463_CR9","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/wnl.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D et al (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84:688\u2013695. https:\/\/doi.org\/10.1212\/wnl.0000000000001256","journal-title":"Neurology"},{"key":"1463_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11916-009-0052-7","volume":"13","author":"TA Smitherman","year":"2009","unstructured":"Smitherman TA, Rains JC, Penzien DB (2009) Psychiatric comorbidities and migraine chronification. Curr Pain Headache Rep 13:326\u2013331. https:\/\/doi.org\/10.1007\/s11916-009-0052-7","journal-title":"Curr Pain Headache Rep"},{"key":"1463_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, van Deun L, van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22:128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"key":"1463_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","volume":"374","author":"LF Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez LF, Raport CJ, Ojala EW et al (2020) Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. J Pharmacol Exp Ther 374:93\u2013103. https:\/\/doi.org\/10.1124\/jpet.119.264671","journal-title":"J Pharmacol Exp Ther"},{"key":"1463_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"key":"1463_CR14","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology 94:e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"key":"1463_CR15","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G et al (2021) Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated during a Migraine Attack: A Randomized Clinical Trial. JAMA 325:2348\u20132356. https:\/\/doi.org\/10.1001\/jama.2021.7665","journal-title":"JAMA"},{"key":"1463_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10194-021-01376-7","volume":"23","author":"P McAllister","year":"2022","unstructured":"McAllister P, Winner PK, Ailani J et al (2022) Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. J Headache Pain 23:22. https:\/\/doi.org\/10.1186\/s10194-021-01376-7","journal-title":"J Headache Pain"},{"key":"1463_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Kolodner K, Bigal ME et al (2009) Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia 29:751\u2013759. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01786.x","journal-title":"Cephalalgia"},{"key":"1463_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963\u2013974. https:\/\/doi.org\/10.1023\/A:1026119331193","journal-title":"Qual Life Res"},{"key":"1463_CR19","doi-asserted-by":"publisher","first-page":"e00567","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker B, Schaeffler B, Beliveau M et al (2020) Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect 8:e00567. https:\/\/doi.org\/10.1002\/prp2.567","journal-title":"Pharmacol Res Perspect"},{"key":"1463_CR20","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/head.12941","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Munjal S, Buse DC et al (2016) Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 56:1635\u20131648. https:\/\/doi.org\/10.1111\/head.12941","journal-title":"Headache"},{"key":"1463_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425255.2022.2049236","volume":"18","author":"S Benemei","year":"2022","unstructured":"Benemei S, Bentivegna E, Martelletti P (2022) Positioning the new drugs for migraine. Expert Opin Drug Metab Toxicol 18:1\u20133. https:\/\/doi.org\/10.1080\/17425255.2022.2049236","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1463_CR22","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, Janelidze M, Chakhava G et al (2020) Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther 42:2254-2265.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2020.11.007","journal-title":"Clin Ther"},{"key":"1463_CR23","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94:e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"key":"1463_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01186-3","volume":"21","author":"S Silberstein","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA et al (2020) Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy\u20132) study. J Headache Pain 21:1\u201312. https:\/\/doi.org\/10.1186\/s10194-020-01186-3","journal-title":"J Headache Pain"},{"key":"1463_CR25","doi-asserted-by":"publisher","unstructured":"McAllister P, Kudrow D, Cady R, et al (2022) Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia. 3331024221089567.https:\/\/doi.org\/10.1177\/03331024221089567","DOI":"10.1177\/03331024221089567"},{"key":"1463_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"H-C Diener","year":"2021","unstructured":"Diener H-C, Marmura MJ, Tepper SJ et al (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache 61:125\u2013136. https:\/\/doi.org\/10.1111\/head.14036","journal-title":"Headache"},{"key":"1463_CR27","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/head.14206","volume":"61","author":"MJ Marmura","year":"2021","unstructured":"Marmura MJ, Diener HC, Cowan RP et al (2021) Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache 61:1421\u20131431. https:\/\/doi.org\/10.1111\/head.14206","journal-title":"Headache"},{"key":"1463_CR28","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R et al (2020) Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on Day 1 after dosing. Headache 60:2220\u20132231. https:\/\/doi.org\/10.1111\/head.14007","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01463-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T20:03:44Z","timestamp":1659038624000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01463-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01463-3","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for each study was provided by the independent ethics committee or institutional review board of the study site. The study was conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Patients provided written informed consent prior to initiation of any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Cady was an employee of Lundbeck at the time of the study.Dr. Lipton has been a consultant, advisory board member, and\/or has received honoraria from Lundbeck Seattle BioPharmaceuticals, Allergan\/Abbvie, American Academy of Neurology, American Headache Society, Amgen, Biohaven Pharmaceuticals, electroCore Medical, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Teva Pharmaceuticals, and Vedanta. He holds stock or stock options in Biohaven Pharmaceuticals and Manistee.Dr. Buse is a part-time employee of Vector Psychometric Group, a company that has received funding from H. Lundbeck A\/S for separate research, has received grant support from the US Food and Drug Administration and the National Headache Foundation, has received grant support and honoraria from Allergan, Amgen, Biohaven, Eli Lilly, Novartis, and Teva, and serves on the editorial board of Current Pain and Headache Reports.Dr. Josiassen, Ms. Lindsten, and Dr. Ettrup are employees of Lundbeck.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}